AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory Effects: Sulindac works by inhibiting the enzyme cyclooxygenase (COX), thereby reducing the production of inflammatory mediators called prostaglandins. By decreasing inflammation, sulindac can alleviate symptoms such as pain and swelling.
Pain Relief: Sulindac is commonly used to relieve pain caused by conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and gout. It can help improve joint function and mobility in individuals with arthritis.
Fever Reduction: Like other NSAIDs, sulindac can also help reduce fever by lowering body temperature. It is sometimes used to manage fever associated with inflammatory conditions.
Analgesic Properties: In addition to its anti-inflammatory effects, sulindac possesses analgesic properties, making it effective in relieving mild to moderate pain.
Gastrointestinal Effects: Sulindac, like other NSAIDs, can increase the risk of gastrointestinal side effects such as stomach ulcers, bleeding, and perforation. These adverse effects may occur more frequently with long-term use or at higher doses.
Cardiovascular Risks: Prolonged use of sulindac or other NSAIDs may be associated with an increased risk of cardiovascular events such as heart attack and stroke, especially in individuals with preexisting cardiovascular conditions or risk factors.
Renal Effects: NSAIDs, including sulindac, can affect kidney function and may lead to fluid retention, electrolyte imbalances, and worsening of kidney function, particularly in susceptible individuals.
Hepatic Effects: Rarely, sulindac may cause liver damage or hepatitis, especially with long-term use or in individuals with preexisting liver conditions.
Hypersensitivity Reactions: Some individuals may experience allergic reactions or hypersensitivity to sulindac, which can manifest as skin rash, itching, swelling, or difficulty breathing. Severe allergic reactions such as anaphylaxis are rare but possible.
Drug Interactions: Sulindac may interact with other medications, including blood thinners, corticosteroids, antihypertensive drugs, and certain antidepressants. It is essential to consult a healthcare provider before taking sulindac concurrently with other medications.
Dosage and Administration: The dosage of sulindac varies depending on the medical condition being treated, the severity of symptoms, and individual patient factors. It is typically taken orally in the form of tablets or capsules, with or without food.
Monitoring: Patients taking sulindac should be closely monitored for therapeutic response and potential adverse effects. Regular follow-up appointments with a healthcare provider are important to assess treatment effectiveness and safety.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.1 | 2 |
| ADHD | 1.9 | 1.9 | |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 1.8 | 0.6 | 2 |
| Allergies | 2 | 1.1 | 0.82 |
| Allergy to milk products | 0.6 | 0.7 | -0.17 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 2.7 | 2.6 | 0.04 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.3 | 1 |
| Ankylosing spondylitis | 1.5 | 1 | 0.5 |
| Anorexia Nervosa | 1.2 | 1.6 | -0.33 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.3 | 1 |
| Asthma | 2.2 | 1.1 | 1 |
| Atherosclerosis | 0.9 | 0.9 | 0 |
| Atrial fibrillation | 2 | 1 | 1 |
| Autism | 3.3 | 3.4 | -0.03 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.1 | 1.1 | |
| Bipolar Disorder | 1.3 | 0.8 | 0.63 |
| Brain Trauma | 0.3 | 1.1 | -2.67 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.3 | 0.6 | -1 |
| Carcinoma | 3 | 1.7 | 0.76 |
| Celiac Disease | 0.9 | 2 | -1.22 |
| Cerebral Palsy | 0.6 | 1.3 | -1.17 |
| Chronic Fatigue Syndrome | 1.8 | 2.9 | -0.61 |
| Chronic Kidney Disease | 1.6 | 0.9 | 0.78 |
| Chronic Lyme | 0.2 | 0.8 | -3 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 1.1 | -0.22 |
| Chronic Urticaria (Hives) | 0.3 | 0 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 3 | 0.8 | 2.75 |
| Colorectal Cancer | 3.4 | 0.8 | 3.25 |
| Constipation | 0.6 | 0.7 | -0.17 |
| Coronary artery disease | 0.7 | 1 | -0.43 |
| COVID-19 | 2.8 | 3.9 | -0.39 |
| Crohn's Disease | 3.9 | 2.6 | 0.5 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1 | -1 | |
| deep vein thrombosis | 1.4 | 1.4 | 0 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 4.4 | 3.4 | 0.29 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.7 | 0.4 | 0.75 |
| Endometriosis | 1.7 | 0.8 | 1.13 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 1 | 0.9 | 0.11 |
| erectile dysfunction | 1 | 1 | |
| Fibromyalgia | 2.1 | 0.3 | 6 |
| Functional constipation / chronic idiopathic constipation | 1.6 | 1.8 | -0.13 |
| gallstone disease (gsd) | 1.5 | 0.8 | 0.88 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.9 | -0.29 |
| Generalized anxiety disorder | 1.1 | 1.1 | 0 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.3 | 2 |
| Graves' disease | 1 | 2.1 | -1.1 |
| Gulf War Syndrome | 0.4 | 0.1 | 3 |
| Halitosis | 1.3 | 0.3 | 3.33 |
| Hashimoto's thyroiditis | 2.2 | 0.7 | 2.14 |
| Heart Failure | 2 | 1 | 1 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hyperglycemia | 0.1 | 0.9 | -8 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 2.1 | 1.9 | 0.11 |
| Hypothyroidism | 0.1 | -0.1 | |
| Hypoxia | 1.3 | 1.3 | |
| IgA nephropathy (IgAN) | 1.6 | 0.7 | 1.29 |
| Inflammatory Bowel Disease | 2.5 | 3.9 | -0.56 |
| Insomnia | 1.3 | 1.6 | -0.23 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 1.4 | 1.4 | |
| Irritable Bowel Syndrome | 2.8 | 1.9 | 0.47 |
| ischemic stroke | 1.4 | 0.8 | 0.75 |
| Liver Cirrhosis | 3.2 | 2.6 | 0.23 |
| Long COVID | 2.1 | 3.8 | -0.81 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.3 | 1 | -2.33 |
| Mast Cell Issues / mastitis | 0.7 | 0.3 | 1.33 |
| ME/CFS with IBS | 0.4 | 0.9 | -1.25 |
| ME/CFS without IBS | 0.4 | 1.1 | -1.75 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 3.8 | 3.2 | 0.19 |
| Mood Disorders | 3.8 | 2.5 | 0.52 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.1 | 2 |
| Multiple Sclerosis | 2.6 | 2.3 | 0.13 |
| Multiple system atrophy (MSA) | 0.3 | 0.4 | -0.33 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.4 | 1 | -1.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.8 | 1.9 | 0.47 |
| NonCeliac Gluten Sensitivity | 0.4 | 0.3 | 0.33 |
| Obesity | 3.3 | 4 | -0.21 |
| obsessive-compulsive disorder | 2.1 | 1.4 | 0.5 |
| Osteoarthritis | 1.2 | 0.9 | 0.33 |
| Osteoporosis | 1.1 | 1.3 | -0.18 |
| pancreatic cancer | 0.7 | 0.3 | 1.33 |
| Parkinson's Disease | 3 | 3.7 | -0.23 |
| Polycystic ovary syndrome | 3.5 | 2.1 | 0.67 |
| Premenstrual dysphoric disorder | 0.1 | 0.4 | -3 |
| primary biliary cholangitis | 0.9 | 0.6 | 0.5 |
| Primary sclerosing cholangitis | 1.6 | 1.8 | -0.13 |
| Psoriasis | 0.8 | 1.5 | -0.88 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.6 | 1.8 | 1 |
| Rosacea | 0.4 | 0.5 | -0.25 |
| Schizophrenia | 2 | 1.7 | 0.18 |
| scoliosis | 0.6 | -0.6 | |
| Sjögren syndrome | 0.9 | 1.4 | -0.56 |
| Sleep Apnea | 1.3 | 1.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 2.1 | 1.3 | 0.62 |
| Systemic Lupus Erythematosus | 1.8 | 1.6 | 0.13 |
| Tic Disorder | 0.6 | 0.6 | 0 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 1.3 | 1.4 | -0.08 |
| Type 2 Diabetes | 3.4 | 2.9 | 0.17 |
| Ulcerative colitis | 2.6 | 2.1 | 0.24 |
| Unhealthy Ageing | 2.6 | 1 | 1.6 |
| Vitiligo | 1.3 | 0.4 | 2.25 |
